GlassScriptPhysician profile
Purvis Collier
NPI 1255665980
$1,777.56
in general payments reported to CMS, 2019-2025
25 companies · $356 in 2025
The $356 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $238 · 2022: $342 · 2023: $421 · 2024: $421 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,197.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $304.12 | 2021-2023 | Trelegy Ellipta |
| Novo Nordisk INC | $288.06 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Viiv Healthcare Company | $152.18 | 2022-2025 | Dovato, Cabenuva, Apretude |
| Lilly USA, LLC | $136.12 | 2022-2024 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $99.44 | 2022-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $97.42 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $83.95 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Sunovion Pharmaceuticals INC. | $82.24 | 2021-2022 | |
| Dexcom, INC. | $68.40 | 2023-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $54.47 | 2022-2023 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $49.85 | 2023-2024 | Verquvo, Belsomra, Steglatro |
| Vertex Pharmaceuticals Incorporated | $44.28 | 2025 | |
| Novartis Pharmaceuticals Corporation | $38.46 | 2022-2023 | |
| Sanofi Pasteur INC. | $37.40 | 2023 | |
| Abbott Laboratories | $35.54 | 2023 | Freestyle Libre 3 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $32.82 | 2025 | |
| Hologic Sales and Service, LLC | $32.38 | 2024 | Aptima |
| Emd Serono, INC. | $29.69 | 2025 | |
| Averitas Pharma INC. | $21.92 | 2025 | Qutenza |
| Novavax INC | $20.25 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Neurocrine Biosciences, INC. | $18.27 | 2024 | Ingrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.56 | 2024 | Jardiance |
| Eisai INC. | $14.40 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.76 | 2023 | |
| Phathom Pharmaceuticals, INC. | $7.58 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Purvis Collier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.